Published in Mol Cell Endocrinol on April 30, 1998
Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem (1996) 1.49
A database of mutants and effects of site-directed mutagenesis experiments on G protein-coupled receptors. Proteins (1996) 1.17
Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation. Mol Pharmacol (1982) 1.16
Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford) (2000) 1.02
Translation of TYMV RNA into high molecular weight proteins. FEBS Lett (1978) 1.00
Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther (1977) 0.96
Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet (1986) 0.96
Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul Pept (1997) 0.95
The catalytic triad in Drosophila alcohol dehydrogenase: pH, temperature and molecular modelling studies. J Mol Biol (1999) 0.92
Cloning of murine SeGpx cDNA and synthesis of mutated GPx proteins in Escherichia coli. Gene (1991) 0.90
Maintenance therapy with a new retard tablet preparation of procainamide. Am Heart J (1976) 0.88
Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol (1986) 0.87
Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model. Eur J Pharmacol (1996) 0.86
Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther (1976) 0.86
Reversal by kappa-agonists of peritoneal irritation-induced ileus and visceral pain in rats. Life Sci (1997) 0.85
Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors. Eur J Pharmacol (1997) 0.85
Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action. Gut (2002) 0.85
Cloning and functional characterization of a novel mas-related gene, modulating intracellular angiotensin II actions. Mol Endocrinol (1991) 0.84
Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes. J Rheumatol (1999) 0.84
Study of a new strain of paramyxoviruses isolated from wild ducks: antigenic and biological properties. J Gen Virol (1979) 0.83
Molecular dynamics of the 5-HT1a receptor and ligands. Protein Eng (1993) 0.83
Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2C receptor interactions. Eur J Pharmacol (1996) 0.83
Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding. Eur J Pharmacol (1986) 0.83
Molecular dynamics of dopamine at the D2 receptor. Proc Natl Acad Sci U S A (1991) 0.82
Mapping the suramin-binding sites of human neutrophil elastase: investigation by fluorescence resonance energy transfer and molecular modeling. Biochemistry (1997) 0.82
[Infectious agents associated with exacerbations of chronic obstructive bronchopneumopathies and asthma attacks]. Rev Mal Respir (1992) 0.81
Antinociceptive effects of neuropeptide Y and related peptides in mice. Brain Res (1996) 0.81
Antinociceptive effects of morphine and U-50,488H on vaginal distension in the anesthetized rat. Life Sci (1997) 0.81
Molecular structure and dynamics of cis(Z)-and trans(E)-flupenthixol and clopenthixol. Pharm Res (1991) 0.80
Ligand induced conformational states of the 5-HT(1A) receptor. Eur J Pharmacol (2001) 0.80
A putative model of the dopamine transporter. Brain Res Mol Brain Res (1994) 0.80
Comparative molecular dynamics of mesophilic and psychrophilic protein homologues studied by 1.2 ns simulations. J Biomol Struct Dyn (1999) 0.80
Salbutamol potentiates the relaxant effects of selective phosphodiesterase inhibitors on guinea pig isolated trachea. Fundam Clin Pharmacol (1996) 0.79
Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci (1988) 0.79
[Systemic manifestations of Parvovirus B19 infections]. Rev Med Interne (2004) 0.79
Effect of the glutathione/glutathione disulfide redox couple on thiopurine methyltransferase. Biochem Pharmacol (2001) 0.78
[Pharmacologic interactions in chronic treatments: corrective measures for its prevention in a basic area of rural health]. Aten Primaria (2001) 0.78
Synthetic cDNA encoding the rat AT1a receptor: a useful tool for structure-function relationship analysis. Biochem Biophys Res Commun (1994) 0.78
Tryptic cleavage of gastric lipases: location of the single disulfide bridge. Biochim Biophys Acta (1994) 0.78
Molecular dynamics of buspirone analogues interacting with the 5-HT1A and 5-HT2A serotonin receptors. Bioorg Med Chem (2001) 0.78
Dog gastric lipase: stimulation of its secretion in vivo and cytolocalization in mucous pit cells. Gastroenterology (1992) 0.78
Influence of the cation on the side-effects of urographic contrast media. Acta Radiol Diagn (Stockh) (1976) 0.78
[The pediatric prescription according to its origin and the motive for the consultation in a basic rural health area]. Aten Primaria (1999) 0.78
Molecular model of the Escherichia coli Na1/H1 antiporter NhaA. Receptors Channels (2001) 0.78
Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat. Psychopharmacology (Berl) (1981) 0.78
Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metab Dispos (1982) 0.78
Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat. Pharmacol Toxicol (1994) 0.77
Anti-apomorphine effects of phenothiazine drug metabolites. Psychopharmacology (Berl) (1987) 0.77
Metabolism of levomepromazine in man. Eur J Drug Metab Pharmacokinet (1995) 0.77
Molecular modelling of UH-301 and 5-HT(1a) receptor interactions. Protein Eng (1996) 0.77
The discriminative stimulus properties of U50,488 and morphine are not shared by fedotozine. Eur Neuropsychopharmacol (1998) 0.77
Organization of the genome of turnip yellow mosaic virus deduced from its messenger properties [proceedings]. Biochem Soc Trans (1979) 0.77
Dihydropyridine-sensitive calcium channel activity related to prolactin, growth hormone, and luteinizing hormone release from anterior pituitary cells in culture: interactions with somatostatin, dopamine, and estrogens. Endocrinology (1988) 0.77
Molecular dynamics of NPY Y1 receptor activation. Bioorg Med Chem (1999) 0.76
Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit (1982) 0.76
Binding modes and pharmacophore modelling of thermolysin inhibitors. Mini Rev Med Chem (2012) 0.76
Differential inhibition by selective phosphodiesterase inhibitors of antigen, LTC4 and histamine-induced contraction of guinea-pig isolated trachea. Pulm Pharmacol (1996) 0.76
Integrated communication between the nervous, endocrine and immune systems. Horm Res (1989) 0.76
High-performance liquid chromatographic determination of levomepromazine (methotrimeprazine) and its main metabolites in serum and urine. Ther Drug Monit (1990) 0.75
Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors. Bioorg Med Chem Lett (2000) 0.75
The difficult challenge of cloning the angiotensin II receptor. Horm Res (1990) 0.75
The complete cDNA sequence encoding dog gastric lipase. DNA Seq (1998) 0.75
Plasma and erythrocyte levels of methotrimeprazine and two of its nonpolar metabolites in psychiatric patients. Ther Drug Monit (1982) 0.75
Molecular structure and dynamics of tricyclic antidepressant drugs. Eur Neuropsychopharmacol (1991) 0.75
Structure-stability relationships of Gd(III) ion complexes for magnetic resonance imaging. J Med Chem (1991) 0.75
Molecular modeling of neurotransmitter receptors and ligands. Psychopharmacol Ser (1993) 0.75
Molecular dynamics of serotonin and ritanserin interacting with the 5-HT2 receptor. Brain Res Mol Brain Res (1992) 0.75
The ligand-binding site of buspirone analogues at the 5-HT1A receptor. J Pharm Pharmacol (1997) 0.75
Templates and models of monoamine transporter proteins. Curr Med Chem (2011) 0.75
[Meningeal tumor]. Rev Med Interne (1997) 0.75
Gas chromatographic mass spectrometric identification of O-demethylated and mono-hydroxylated metabolites of levomepromazine in blood from psychiatric patients by selected ion recording with high resolution. Biomed Mass Spectrom (1982) 0.75
Molecular structure and dynamics of serotonin. Brain Res Mol Brain Res (1991) 0.75
[Seropositivity. The seropositive patient in the day hospital. Admission]. Soins (1998) 0.75
[Is angiotensin II a growth factor?]. Diabete Metab (1992) 0.75
Classification of neuroleptics based on their pharmacokinetics. Clin Neuropharmacol (1986) 0.75
Human brain receptors, III. Molecular Model: G protein-coupled receptor. Am J Psychiatry (1994) 0.75
Pharmacokinetics and first-pass metabolism of levomepromazine in the rat. Acta Pharmacol Toxicol (Copenh) (1982) 0.75
Arachidonate metabolism in the anterior pituitary: effect of arachidonate inhibitors on Basal and stimulated secretion of prolactin, growth hormone and luteinizing hormone. I. Hormone release from incubated or perifused pituitary fragments. J Neuroendocrinol (1990) 0.75
Anticholinergic and cardiodepressive effects of levomepromazine and two of its metabolites on isolated rat atria. Eur J Pharmacol (1976) 0.75
Molecular modeling of antipsychotic drugs and G protein coupled receptors. Therapie (1992) 0.75
Pharmacokinetic and pharmacodynamic factors causing variability in response to neuroleptic drugs. Psychopharmacol Ser (1987) 0.75
Molecular modeling of the endogenous peptide Leu-Ser-Ala-Leu, pindolol, 5-hydroxytryptamine and their interactions with the human 5-hydroxytryptamine1B (5-HT1B) receptor. Receptors Channels (1998) 0.75
tRNA nucleotidyltransferase-catalyzed incorporation of CMP and AMP into RNA-bacteriophage genome fragments. Eur J Biochem (1975) 0.75
Molecular structure and dynamics of acetylcholine. J Neural Transm Gen Sect (1991) 0.75
GLC determination of methotrimeprazine and its sulfoxide in plasma. J Pharm Sci (1976) 0.75
Antagonism of presynaptic dopamine receptors by phenothiazine drug metabolites. Life Sci (1990) 0.75
Weight variation of tablets based on small-scale production. Pharm Acta Helv (1969) 0.75
[Letter: Apparent distribution volume, an ambiguous concept in pharmacokinetics]. Tidsskr Nor Laegeforen (1976) 0.75
Differential effects of fedotozine compared to other kappa agonists on diuresis in rats. J Pharmacol Exp Ther (1996) 0.75
Three-dimensional structure and molecular dynamics of cis(Z)- and trans(E)-chlorprothixene. J Pharm Sci (1991) 0.75
Identification of nonpolar methotrimeprazine metabolites in plasma and urine by GLC-mass spectrometry. J Pharm Sci (1977) 0.75
Molecular structure and dynamics of the four 10-hydroxynortriptyline isomers. Neuropsychopharmacology (1992) 0.75
Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol (1977) 0.75
Pharmaceutical and pharmacokinetic principles in the formulation of a sustained-release procainamide tablet. Pharm Acta Helv (1976) 0.75
High-performance liquid chromatography of levomepromazine (methotrimeprazine) and its main metabolites. J Chromatogr (1990) 0.75
Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology (1981) 0.75